TEZEPELUMAB
Tezepelumab 210 mg/1.91 mL injection, 1.91 mL pen device
TEZEPELUMAB (15363N)
15363N
Manner of administration:Injection
Restriction
Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patients; or Recommencement of treatment in a new
treatment cycle following a break in PBS-subsidised biological medicine therapy)
Restriction
Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Restriction
Indication: Uncontrolled severe asthma
Treatment phase: Grandfathering arrangements - Transitioning from non-PBS to PBS-subsidised supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 7 | DPMQ: $1,721.02 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tezspire | |||||